HC Wainwright Reaffirms Buy Rating for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Catalyst Pharmaceuticals (NASDAQ:CPRX)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued on Friday,Benzinga reports. They currently have a $30.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 25.37% from the company’s previous close.

Several other equities analysts have also recently weighed in on the stock. Citigroup raised their target price on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Truist Financial raised their price objective on Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $29.50.

Catalyst Pharmaceuticals Stock Up 2.9 %

NASDAQ CPRX opened at $23.93 on Friday. The business has a 50-day moving average price of $20.74 and a 200-day moving average price of $18.09. The firm has a market cap of $2.85 billion, a price-to-earnings ratio of 20.28, a price-to-earnings-growth ratio of 3.62 and a beta of 0.75. Catalyst Pharmaceuticals has a twelve month low of $12.27 and a twelve month high of $24.27.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.13. Catalyst Pharmaceuticals had a return on equity of 43.57% and a net margin of 31.01%. The business had revenue of $122.71 million during the quarter, compared to the consensus estimate of $111.76 million. Research analysts expect that Catalyst Pharmaceuticals will post 1.82 EPS for the current fiscal year.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, Director David S. Tierney sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total transaction of $301,500.00. Following the sale, the director now directly owns 348,874 shares of the company’s stock, valued at $7,012,367.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, insider Steve Miller sold 150,000 shares of the stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $20.35, for a total value of $3,052,500.00. Following the sale, the insider now owns 675,124 shares of the company’s stock, valued at approximately $13,738,773.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director David S. Tierney sold 15,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total transaction of $301,500.00. Following the transaction, the director now directly owns 348,874 shares of the company’s stock, valued at approximately $7,012,367.40. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 11.00% of the company’s stock.

Institutional Trading of Catalyst Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. Intech Investment Management LLC bought a new position in shares of Catalyst Pharmaceuticals during the third quarter valued at approximately $644,000. Advisors Asset Management Inc. boosted its holdings in Catalyst Pharmaceuticals by 6.9% during the 3rd quarter. Advisors Asset Management Inc. now owns 177,333 shares of the biopharmaceutical company’s stock valued at $3,525,000 after acquiring an additional 11,484 shares during the period. Connor Clark & Lunn Investment Management Ltd. bought a new position in Catalyst Pharmaceuticals in the 3rd quarter valued at $200,000. Segall Bryant & Hamill LLC bought a new position in Catalyst Pharmaceuticals in the 3rd quarter valued at $808,000. Finally, Quest Partners LLC increased its stake in Catalyst Pharmaceuticals by 36,146.6% in the third quarter. Quest Partners LLC now owns 37,334 shares of the biopharmaceutical company’s stock worth $742,000 after purchasing an additional 37,231 shares during the period. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.